Trial Profile
Pilot study using neoadjuvant chemo-radiotherapy and EGFR-tyrosine kinase inhibitor for potentially resectable pancreatic cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 07 Dec 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 07 Dec 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 07 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.